From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switchingMariangela Gaudio, Alberto Zambelli, Greta Schivardi et al.|Tumori Journal|2025Cited by 0